DUBLIN--(BUSINESS WIRE)--The "Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global doxorubicin market reached a value of US$ 1.12 Billion in 2021. Looking forward, the market to reach a value of US$ 1.62 Billion by 2027, exhibiting a CAGR of 6.34% during 2021-2027.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Doxorubicin Market Trends:
The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas.
Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies.
Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer.
As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations.
Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.
Key Questions Answered in This Report:
- How has the global doxorubicin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global doxorubicin market?
- What are the key regional markets?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global doxorubicin market and who are the key players?
- What is the degree of competition in the industry?
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being
- Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
- Baxter International Inc.
- Cadila Pharmaceuticals
- Cipla Inc.
- Hikma Pharmaceuticals PLC
- Meiji Holdings Co. Ltd.
- Novartis AG
- Pfizer Inc.
Key Market Segmentation:
Breakup by Application:
- Breast Cancer
- Ovarian Cancer
- Multiple Myeloma
- Kaposi Sarcoma
- Leukemia
- Bone Sarcoma
- Endometrial Cancer
- Others
Breakup by Distribution Channel:
- Hospital and Retail Pharmacies
- Online Stores
- Others
Breakup by Region:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/nx8v55
